Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
49.27
+2.42 (5.17%)
Sep 27, 2024, 4:00 PM EDT - Market closed
Legend Biotech Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 81.08, with a low estimate of 60 and a high estimate of 94. The average target predicts an increase of 64.56% from the current stock price of 49.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 7 | 6 | 7 | 8 | 7 | 7 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $86 | Buy | Reiterates | $86 | +74.55% | Sep 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +48.16% | Aug 28, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $86 | Buy | Reiterates | $86 | +74.55% | Aug 12, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $70 → $76 | Buy | Maintains | $70 → $76 | +54.25% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +48.16% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
595.82M
from 285.14M
Increased by 108.95%
Revenue Next Year
1.08B
from 595.82M
Increased by 81.26%
EPS This Year
-1.40
from -2.94
EPS Next Year
-0.83
from -1.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 671.0M | 1.4B | 2.3B | ||
| Avg | 595.8M | 1.1B | 1.7B | ||
| Low | 454.6M | 844.8M | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 135.3% | 131.1% | 111.6% | ||
| Avg | 109.0% | 81.3% | 56.7% | ||
| Low | 59.4% | 41.8% | 11.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.76 | 0.40 | 1.72 | ||
| Avg | -1.40 | -0.83 | 0.79 | ||
| Low | -1.68 | -1.60 | -0.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.